Top

Published in:

01-07-2019 | Systematic Review

Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications

Authors: Carla Carnovale, Marco Pozzi, Faizan Mazhar, Giulia Mosini, Marta Gentili, Gabriëlla G. A. M. Peeters, Emilio Clementi, Sonia Radice

Published in: Clinical Pharmacokinetics | Issue 7/2019

Abstract

Introduction

Qualitative studies on drug–drug interactions (DDIs) between anticonvulsants and antibiotics report pharmacokinetic changes that may increase the clinical risks in terms of adverse drug reactions (ADRs) and efficacy. However, no studies have provided a systematic and quantitative analysis of anticonvulsant–antibiotic pharmacokinetic DDIs. To provide such indications, we systematically and critically reviewed the literature on anticonvulsant–antibiotic DDIs in terms of quantitative pharmacokinetic changes and related ADRs. We also investigated less-known interactions for the possible occurrence of clinically relevant events.

Methods

We conducted a systematic review of all reports of DDIs between anticonvulsants and antibiotics assessing pharmacokinetic parameters published until 9 June 2017.

Results

We were able to meta-analyse the effect of macrolides on carbamazepine area under the concentration-time curve from time zero to infinity [AUC_∞] (+ 34.5 µg/mL*h, p = 0.005, n = 38), clearance (− 2.88 mL/min, p < 0.001, n = 46) and trough plasma concentration [Ct] (+ 8.0 µg/mL, p = 0.002, n = 23), and of carbapenems on valproic acid Ct (− 42.9 µg/mL, p < 0.001, n = 262). Pharmacokinetic parameters with other DDIs were insufficiently reported to allow a statistical analysis.

Conclusions

Therapeutic drug monitoring in patients receiving long-term antiepileptic therapies may help, in specific conditions, to improve safety while preserving efficacy. Such a procedure would also increase scientific information on how pharmacokinetic variations are associated with ADR occurrence, and possibly epileptological outcomes for those DDIs for which available information is suggestive of a relevant effect but is not yet sufficient to draw conclusions.

Available only for authorised users

World Health Organization. Epilepsy. Available at: http://www.who.int/en/news-room/fact-sheets/detail/epilepsy. Accessed 27 Apr 2018.

Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119–40.PubMed

Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473–81.PubMed

Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–55.PubMed

Loiseau P. Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance. Drug Saf. 1998;19(6):495–510.PubMed

Esposito S, Canevini MP, Principi N. Complications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugs. Int J Antimicrob Agents. 2017;50(1):1–8.PubMed

Strazzer S, Pozzi M, Avantaggiato P, Zanotta N, Epifanio R, Beretta E, et al. Late post-traumatic epilepsy in children and young adults: impropriety of long-term antiepileptic prophylaxis and risks in tapering. Paediatr Drugs. 2016;18(3):235–42.PubMed

Chu-Shore CJ, Thiele EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol. 2010;17(4):214–23.PubMed

Guerrini R, Zaccara G, la Marca G, Rosati A. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf. 2012;35(7):519–33.PubMed

10.

Shih JJ, Whitlock JB, Chimato N, Vargas E, Karceski SC, Frank RD. Epilepsy treatment in adults and adolescents: expert opinion, 2016. Epilepsy Behav. 2017;69:186–222.PubMed

11.

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9–62.PubMed

12.

Landmark CJ, Johannessen SI, Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016;18(4):367–83.PubMed

13.

Fudio S, Carcas A, Piñana E, Ortega R. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J Clin Pharm Ther. 2006;31(4):393–6.PubMed

14.

De Turck BJ. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998;42(4):563–4.PubMed

15.

Carranco E, Kareus J, Co S, Peak V, Al-Rajeh S. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol. 1985;42(2):187–8.PubMed

16.

Berrettini WH. A case of erythromycin-induced carbamazepine toxicity. J Clin Psychiatry. 1986;47(3):147.PubMed

17.

Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, et al. Drug interactions with clinafloxacin. Antimicrob Agents Chemother. 2001;45(9):2543–52.PubMedPubMedCentral

18.

Albin H, Vinçon G, Pehourcq F, Dangoumau J. Influence of josamycine treatment on carbamazepine kinetics. Therapie. 1982;37(2):151–6.PubMed

19.

Barzaghi N, Gatti G, Crema F, Monteleone M, Amione C, Leone L, et al. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol. 1987;24(6):836–8.PubMedPubMedCentral

20.

Barzaghi N, Gatti G, Crema F, Faja A, Monteleone M, Amione C, et al. Effect of flurithromycin, a new macrolide antibiotic, on carbamazepine disposition in normal subjects. Int J Clin Pharmacol Res. 1988;8(2):101–5.PubMed

21.

Couet W, Istin B, Ingrand I, Girault J, Fourtillan JB. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Ther Drug Monit. 1990;12(2):144–9.PubMed

22.

Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther. 1983;33(4):460–4.PubMed

23.

Goulden KJ, Camfield PR, Camfield CS, Tibbles JA, Dooley JM, Fraser AD, et al. Changes in serum anticonvulsant levels with febrile illness in children with epilepsy. Can J Neurol Sci. 1988;15(3):281–5.PubMed

24.

Mesdjian E, Dravet C, Cenraud B, Roger J. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia. 1980;21(5):489–96.PubMed

25.

O’Connor NK, Fris J. Clarithromycin-carbamazepine interaction in a clinical setting. J Am Board Fam Pract. 1994;7(6):489–92.PubMed

26.

Vinçon G, Albin H, Demotes-Mainard F, Guyot M, Bistue C, Loiseau P. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol. 1987;32(3):321–3.PubMed

27.

Albani F, Riva R, Baruzzi A, Genton P, Portera-Sanchez A, Lipinski CG. Clarithromycin-carbamazepine interaction: a case report. Epilepsia. 1993;34(1):161–2.PubMed

28.

Dravet C, Mesdjian E, Cenraud B, Roger J. Interaction between carbamazepine and triacetyloleandomycin. Lancet. 1977;1(8015):810–1.PubMed

29.

Gélisse P, Hillaire-Buys D, Halaili E, Jean-Pastor MJ, Vespignan H, Coubes P, et al. Carbamazepine and clarithromycin: a clinically relevant drug interaction. Rev Neurol (Paris). 2007;163(11):1096–9.

30.

Goulden KJ, Camfield P, Dooley JM, Fraser A, Meek DC, Renton KW, et al. Severe carbamazepine intoxication after coadministration of erythromycin. Clinical and laboratory observations. J Pediatr. 1986;109(1):135–8.PubMed

31.

Leclercq V, Lacaille S, Delpierre S, Karoubi E, Legrain S. Avoidable adverse event: carbamazepine encephalopathy when introducing clarithromycine. Rev Med Interne. 2005;26(10):835–6.PubMed

32.

Loiseau P, Guyot M, Pautrizel B, Vincon G, Albin H. Carbamazepine intoxication caused by the interaction of carbamazepine-erythromycin. Presse Med. 1985;14(3):162.PubMed

33.

Macnab AJ, Robinson JL, Adderly RJ, D’Orsogna L. Heart block secondary to erythromycin-induced carbamazepine toxicity. Pediatrics. 1987;80(6):951–3.PubMed

34.

Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR. Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med. 1995;149(1):99–101.PubMed

35.

Tagawa T, Mimaki T, Ono J, Tanaka J, Suzuki Y, Itagaki T, et al. Erythromycin-induced carbamazepine intoxication in two epileptic children. Jpn J Psychiatry Neurol. 1989;43:513–4.PubMed

36.

Viani F, Claris-Appiani A, Rossi LN, Giani M, Romeo A. Severe hepatorenal failure in a child receiving carbamazepine and erythromycin F. Eur J Pediatr. 1992;151(9):715.PubMed

37.

Woody RC, Kearns GL, Bolyard KJ. Carbamazepine intoxication following the use of erythromycin in children. Pediatr Infect Dis J. 1987;6(6):578–9.PubMed

38.

Yasui N, Otani K, Kaneko S, Shimoyama R, Ohkubo T, Sugawara K. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. Int Clin Psychopharmacol. 1997;12(4):225–9.PubMed

39.

Zitelli BJ, Howrie DL, Altman H, Maroon TJ. Erythromycin-induced drug interactions. An illustrative case and review of the literature. Clin Pediatr (Phila). 1987;26(3):117–9.

40.

Huang CR, Lin CH, Hsiao SC, Chen NC, Tsai WC, Chen SD, et al. Drug interaction between valproic acid and carbapenems in patients with epileptic seizures. Kaohsiung J Med Sci. 2017;33(3):130–6.PubMed

41.

Mink S, Muroi C, Seule M, Bjeljac M, Keller E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2011;113(8):644–8.PubMed

42.

Park MK, Lim KS, Kim TE, Han HK, Yi SJ, Shin KH, et al. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. Ther Drug Monit. 2012;34(5):599–603.PubMed

43.

Spriet I, Goyens J, Meersseman W, Wilmer A, Willems L, Van Paesschen W. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007;41(7):1130–6.PubMed

44.

Tobin JK, Golightly LK, Kick SD, Jones MA. Valproic acid-carbapenem interaction: report of six cases and a review of the literature. Drug Metabol Drug Interact. 2009;24(2–4):153–82.PubMed

45.

Wen ZP, Fan SS, Du C, Yin T, Zhou BT, Peng ZF, et al. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther. 2017;42(2):221–7.PubMed

46.

Haroutiunian S, Ratz Y, Rabinovich B, Adam M, Hoffman A. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. J Clin Pharmacol. 2009;49(11):1363–9.PubMed

47.

Miranda Herrero MC, Alcaraz Romero AJ, Escudero Vilaplana V, Fernández Lafever SN, Fernández-Llamazares CM, Barredo Valderrama E, et al. Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics? Eur J Paediatr Neurol. 2015;19(2):155–61.PubMed

48.

Wu CC, Pai TY, Hsiao FY, Shen LJ, Wu FL. The effect of different carbapenem antibiotics (ertapenem, imipenem/cilastatin, and meropenem) on serum valproic acid concentrations. Ther Drug Monit. 2016;38(5):587–92.PubMed

49.

Borobia AM, Fudio S, Carcas Sansuán AJ. Valproate-meropenem co-administration, an example of information shortcomings in relevant drug interactions [in Spanish]. Med Clin (Barc). 2009;132(20):803–4.PubMed

50.

Vélez Díaz-Pallarés M, Delgado Silveira E, Alvarez Díaz AM, Pérez Menéndez-Conde C, Vicente Oliveros N, Bermejo Vicedo T. Analysis of the valproic acid-meropenem interaction in hospitalised patients. Neurologia. 2012;27(1):34–8.PubMed

51.

Berardi D, Clemente R, Finn BC, Bruetman JE, Young P. Not to forget interaction between meropenem and valproic acid. Rev Med Chil. 2014;142(3):400–1.PubMed

52.

Cabanes Mariscal MA, Sánchez López P, Alvarez Herranz P, Chamorro Merino G. Pharmacokinetic interaction between valproic acid and ertapenem. Farm Hosp. 2006;30(5):313–5.PubMed

53.

Clause D, Decleire PY, Vanbinst R, Soyer A, Hantson P. Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Med. 2005;31(9):1293–4.PubMed

54.

González C, Villena R. Pharmacological interaction between meropenem and valproic acid: a report of two cases. Rev Chilena Infectol. 2012;29(3):353–5.PubMed

55.

Lee SG, Kim JH, Joo JY, Kwon OH. Seven cases of decreased serum valproic acid concentration during concomitant use of carbapenem antibiotics [in Korean]. Korean J Lab Med. 2007;27(5):338–43.PubMed

56.

Llinares Tello F, Bosacoma Ros N, Hernández Prats C, Climent Grana E, Selva Otaolaurruchi J, Ordovás Baines JP. Pharmacokinetic interaction between valproic acid and carbapenem-like antibiotics: a discussion of three cases. Farm Hosp. 2003;27(4):258–63.PubMed

57.

Molnar GP, Stephens KJ, George LV, Stewart JT. A critical interaction between ertapenem and valproic acid. J Clin Psychopharmacol. 2015;35(3):348–50.PubMed

58.

Muzyk AJ, Candeloro CL, Christopher EJ. Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder. Gen Hosp Psychiatry. 2010;32(5):560.e1–3.

59.

Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004;31(3):232–4.PubMed

60.

Nagai K, Shimizu T, Togo A, Takeya M, Yokomizo Y, Sakata Y, Matsuishi T, Kato H. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother. 1997;39(2):295–6.PubMed

61.

Paulzen M, Eap CB, Gründer G, Kuzin M. Pharmacokinetic interaction between valproic acid, meropenem, and risperidone. J Clin Psychopharmacol. 2016;36(1):90–2.PubMed

62.

Perea Falomir M, Roura Poch P, Higueruelo Demasón S, García Gil VJ. Pharmacokinetic interaction between valproic acid and imipenem. Farm Hosp. 2006;30(5):316–7.PubMed

63.

San Antonio Arce V, Joyanes Abancens B. Meropenem and valproic acid. An interaction to remember. An Pediatr (Barc). 2009;70(2):193–4.

64.

Suntimaleeworakul W, Patharachayakul S, Chusri S. Drug interaction between valproic acid and meropenem: a case report. J Med Assoc Thai. 2012;95(2):293–5.PubMed

65.

Yoon H, Kim DH. Unusual drug reaction between valproate sodium and meropenem. Int J Clin Pharm. 2013;35(3):316–8.PubMed

66.

Coves-Orts FJ, Borrás-Blasco J, Navarro-Ruiz A, Murcia-López A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005;39(3):533–7.PubMed

67.

Fernández García MI, Fernández de la Puebla Giménez RÁ, García Olid B, Torres Degayón V. Meropenem decreases valproate plasmatic concentrations. Med Clin (Barc). 2011;137(1):43–4.

68.

Gu J, Huang Y. Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient. Am J Geriatr Pharmacother. 2009;7(1):26–33.PubMed

69.

Pérez Plasencia A, Soy D, Nicolas JM. Pharmacokinetic interaction between valproic acid and meropenem. Med Clin (Barc). 2004;123(1):38–9.PubMed

70.

Sala Piñol F, Padullés Zamora N, Hidalgo Albert E, Clemente Bautista S, Cabañas Poy MJ, Oliveras Arenas M, et al. Pharmacokinetic interaction between valproic acid and meropenem. An Pediatr (Barc). 2006;64(1):93–5.PubMed

71.

Shihyakugari A, Miki A, Nakamoto N, Satoh H, Sawada Y. First case report of suspected onset of convulsive seizures due to co-administration of valproic acid and tebipenem. Int J Clin Pharmacol Ther. 2015;53(1):92–6.PubMed

72.

Spriet I, Willems L. No interaction between valproate and meropenem in a cirrhotic patient. Ann Pharmacother. 2011;45(9):1167–8.PubMed

73.

Bates D, Parkins M, Duggan K. Ertapenem-induced reduction in valproate levels: case report and review of the literature. Can J Hosp Pharm. 2010;63(4):315–22.PubMedPubMedCentral

74.

Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy. 2007;27(8):1202–5.PubMed

75.

Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased serum valproate during meropenem therapy. J Child Neurol. 2005;20(5):456–7.PubMed

76.

Yamagata T, Momoi MY, Murai K, Ikematsu K, Suwa K, Sakamoto K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit. 1998;20(4):396–400.PubMed

77.

Alemán A, Martín Romano L. Valproic acid and meropenem, a bad association. Description of two cases and review of the literature. Neurol Arg. 2012;4:126–31.

78.

Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L. Single dose phenytoin clearance during erythromycin treatment. Res Commun Chem Pathol Pharmacol. 1984;46(2):207–17.PubMed

79.

Milne RW, Coulthard K, Nation RL, Penna AC, Roberts G, Sansom LN. Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin. Br J Clin Pharmacol. 1988;26(3):330–3.PubMedPubMedCentral

80.

Hansen JM, Kampmann JP, Siersbaek-Nielsen K, Lumholtz IB, Arrøe M, Abildgaard U, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl. 1979;624:106–10.PubMed

81.

Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. Br J Clin Pharmacol. 2011;71(4):544–9.PubMedPubMedCentral

82.

Lee SY, Huh W, Jung JA, Yoo HM, Ko JW, Kim JR. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid. Drug Des Devel Ther. 2015;9:4559–63.PubMedPubMedCentral

83.

Sachdeo RC, Narang-Sachdeo S, Montgomery PA, Shumaker RC, Perhach JL, Lyness WH, et al. Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy. J Clin Pharmacol. 1998;38(2):184–90.PubMed

84.

Keränen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand. 1992;86(2):120–3.PubMed

85.

Santucci R, Fothergill H, Laugel V, Perville A, De Saint Martin A, Gerout AC, et al. The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy. Br J Clin Pharmacol. 2010;69(3):314–6.PubMedPubMedCentral

86.

Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial. Clin Drug Investig. 2015;35(5):299–305.PubMed

87.

Thomsen MS, Groes L, Agersø H, Kruse T. Lack of pharmacokinetic interaction between tiagabine and erythromycin. J Clin Pharmacol. 1998;38(11):1051–6.PubMed

88.

Harder S, Schneider W, Bae ZU, Bock U, Zielen S. Undesirable drug reactions in simultaneous administration of high-dosage phenobarbital and beta-lactam antibiotics. Klin Padiatr. 1990;202(6):404–7.PubMed

89.

Dillard ML, Fink RM, Parkerson R. Ciprofloxacin-phenytoin interaction. Ann Pharmacother. 1992;26(2):263.PubMed

90.

Hull RL. Possible phenytoin-ciprofloxacin interaction. Ann Pharmacother. 1993;27(10):1283.PubMed

91.

McLeod R, Trinkle R. Comment: unexpectedly low phenytoin concentration in a patient receiving ciprofloxacin. Ann Pharmacother. 1998;32(10):1110–1.PubMed

92.

Otero MJ, Morán D, Valverde MP. Interaction between phenytoin and ciprofloxacin. Ann Pharmacother. 1999;33(2):251–2.PubMed

93.

Pollak PT, Slayter KL. Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin. Ann Pharmacother. 1997;31(1):61–4.PubMed

94.

Pollak PT, Slayter KL. Comment: ciprofloxacin-phenytoin interaction. Ann Pharmacother. 1997;31(12):1549–50.PubMed

95.

Mileusnic D, Donoghue ER, Lifschultz BD. Pathological case of the month: sudden death in a child as a result of pancreatitis during valproic acid therapy. Pediatr Pathol Mol Med. 2002;21(5):477–84.PubMed

96.

Lowry JA, et al. Unusual presentation of iatrogenic phenytoin toxicity in a newborn. J Med Toxicol. 2005;1(1):26–9.PubMedPubMedCentral

97.

Catalá Ripoll JV, Domingo Chiva E, Marco del Río J. Interaction between levofloxacin and phenytoin: report of two cases. Med Clin (Barc). 2017;149(6):278–9.

98.

Gillman MA, Sandyk R. Phenytoin toxicity and co-trimoxazole. Ann Intern Med. 1985;102(4):559.PubMed

99.

Avanzini G, Depaulis A, Tassinari A, de Curtis M. Do seizures and epileptic activity worsen epilepsy and deteriorate cognitive function? Epilepsia. 2013;54(Suppl 8):14–21.PubMed

100.

Kataria L, Vaughn BV. Sleep and Epilepsy. Sleep Med Clin. 2016;11(1):25–38.PubMed

Title: Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications
Authors: Carla Carnovale
Marco Pozzi
Faizan Mazhar
Giulia Mosini
Marta Gentili
Gabriëlla G. A. M. Peeters
Emilio Clementi
Sonia Radice
Publication date: 01-07-2019
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 7/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-018-0720-z

At a glance: The STEP trials

Springer Medicine

Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2019

Author’s Reply to Trechot: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults

Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort

Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?